OLINVYK (oliceridine)
Acute Pain
ApprovedCommercial
Key Facts
About Trevena
Trevena's mission is to develop safer and more effective CNS therapies by exploiting biased ligand signaling at G protein-coupled receptors (GPCRs). Its primary achievement is the 2020 FDA approval of OLINVYK, a biased mu-opioid receptor agonist for acute pain, though commercial uptake has been limited. The company's current strategy is to advance its early-stage pipeline, including TRV045 for neuropathic pain and epilepsy, while navigating severe financial constraints and seeking strategic alternatives to sustain operations.
View full company profileTherapeutic Areas
Other Acute Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| GRC 27864 | glenmark | Phase 2 |
| Cebranopadol | Tris Pharma | Phase 3 |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical or Phase 1 |
| VX-548 | Vertex Pharmaceuticals | Phase 3 |
| Maxigesic® Oral | AFT Pharmaceuticals | Approved |